Patient Reported Outcomes
Improving Quality, Value, and Outcomes with Patient-Reported Outcomes

Welcome

Tricia Lee Wilkins
Director, Pharmacy Affairs
Academy of Managed Care Pharmacy

Disclaimer
Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. Commercial purposes include but are not limited to symposia, educational programs, and other forms of presentation, whether developed or offered by for-profit or not-for-profit entities, and that involve funding from for-profit firms or a registration fee that is other than nominal. In addition, organizations may not widely redistribute or re-use this webinar material without the written consent of the presenter, the person or organization holding copyright to the material (if applicable), and AMCP. This includes large quantity redistribution of the material or storage of the material on electronic systems for other than personal use.
AMCP Partnership Forums
Collaboration for Optimization

The live, hands-on AMCP Partnership Forums bring key decision-makers in managed care, integrated care, the pharmaceutical industry, and others together to discuss and collaborate on tactics and strategies to drive efficiencies and outcomes in integrated care and managed care.

Partnership Forums...

- Proactive, collaborative approach to solving key health care issues
- Provide a voice to all stakeholders
- Gain consensus on tactics to address challenges and opportunities
- Work together on common goals and interests
- High visibility among industry and policy stakeholders
2017 Partnership Forums

Advancing Value-Based Contracting

Patient Reported Outcomes

Driving Value and Outcomes in Oncology

Managing Care in the Wave of Precision Medicine

PRO Sponsors
Our Faculty

Sheila Thomas  
Sr. Director, Global Health Economics and Value Assessment, Sanofi

Lisa Opipari-Arrigan  
Associate Professor, Cincinnati Children’s Medical Center

Kellie Meyer  
Senior Director, Global Health Economics and Outcomes Research  
Xcenda, Amerisource Bergen

Agenda

- Why Patient Reported Outcomes Forum?
- Forum Findings and Recommendations
- Q&A
- Next Steps and Action Items
How to Ask Questions

Why a PRO Partnership Forum?

PROs represent a key component of the shift towards patient-centered healthcare
**Forum Participants**

25+ participants from health plans, integrated delivery systems, pharmacy benefit managers, employers, data and analytics experts, biopharmaceutical companies and government agencies

- Amgen
- Accelerated Cure Project for Multiple Sclerosis
- Aetna
- Allergan
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Cincinnati Children’s Hospital Medical Center
- CMS
- FDA/CDER
- Genentech
- GlaxoSmithKline
- Global Healthy Living Foundation (GHLF)
- Healthagen
- Inova Center for Personalized Health
- National Quality Forum
- Novartis Pharmaceuticals
- Novo Nordisk
- OptumRx
- PCORI (Patient Centered Outcomes Research Institute)
- Pharmacy Quality Alliance
- Precision For Value
- Premier
- Regal Medical Group
- Sanofi
- Takeda Pharmaceuticals
- The Ohio State University Health Plan, Inc.
- UPMC Health Plan
- Vital Score
- Walgreens
- Xcenda/AmerisourceBergen

**PROs Have a Number of Benefits**

- PROs are direct measures of patients’ disease symptoms or characteristics that should be addressed and/or maintained
- Understanding patient needs and preferences can promote better patient care
- Allocate resources and define priorities
  - Develop better treatment plans & inform guideline development
  - Guide research to drive patient-centric care

©2018 AMCP Partnership Forums
## Current Use of Pros

1. Assessing symptom severity
2. Informing treatment decisions
3. Determining patient preferences
4. Connecting clinicians to patient-generated data
5. Tracking outcomes
6. Prioritizing patient-clinician discussions
7. Monitoring general health and well-being
8. Evaluating population health initiatives

## PRO Challenges

- A clear and consistently defined methodology for developing, collecting, and using PROs
- Engaging patients throughout the entire PRO process
- Limited technology infrastructure
PRO Forum Goals

1. Determine how PROs are used in drug development and quality performance standards
2. Address obstacles that impact PRO utilization
3. Identify an ideal future state where PROs are used to maximize the goals of all healthcare stakeholders
4. Determine what actionable steps need to be taken to make an ideal future state reality

Consensus

1. PROs are crucial in defining value, improving patient care, and implementing value-based payment models.
2. Significant organizational and operational factors are needed to achieve adoption and use.
PRO Expansion Opportunities

Drug Development
Integration into clinical trial design and FDA drug and product labels

Clinical Care
Better align clinician and patient priorities

Formulary and coverage decision-making
Improve coverage decision-making and be used as a component of value-based contracting models

PRO Challenges

PRO Utilization in Drug Development and Quality Measures
Drug Development Challenges

- **Patient Populations**
  - Often not representative of patients who use the treatments in real-world settings

- **Drug Labeling**
  - Exploratory endpoints preventing making claims, such as comparisons across therapies

- **Continuous Data Collection**
  - Requiring organizations to commit significant time and resources

Drug Development Recommendations

1. Broaden representative populations
2. Early alignment in drug development
3. Streamline data collection by engaging non-physician healthcare professionals
PRO Challenges

PRO Utilization in Patient Care

Clinical Utilization Challenges

PRO Data Collection and Analysis

Requires significant effort, so organizations must commit time and resources to use PROs

Standardization versus Custom PROs

Disease-specific PROs can better capture the continuum, but they often do not have the same validation
Clinical Utilization Challenges

Technology

Current collection methods can be time and resource intensive for both patients and clinicians

Predictive Analysis

PROs capture present and/or past patient data, but often not a patient’s future health state or resource use

Utilization Recommendations

1. Better integration of PROs into EHRs
2. Ensure data is actionable
3. Data integrated into claims data
4. Common technology platforms (i.e. smart phones)
5. Greater emphasis on predictive design
Ideal Future State

Unique Priorities of Key PRO Stakeholders

**Patients / Advocacy**
- Simple, customizable PROs that reflect patient literacy and contextual factors
- Easy collection process
- Presented in a manner that is easily understood

**Clinicians**
- Standard data collection and technology
- Incentives or goals to ensure collection of PROs
- PROs that can facilitate care decisions, streamline care, and align patient and clinician goals
### Unique Priorities of Key PRO Stakeholders

<table>
<thead>
<tr>
<th>Payers</th>
<th>Manufacturers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prioritized PRO that were universally useful and relevant for all stakeholders</td>
<td>Widespread use in clinical trials to support the drug approval process</td>
</tr>
<tr>
<td>Used to make informed decision-making, resource utilization and developing care pathways</td>
<td>PROs must be scalable and representative broad patient population and useable in real-world settings</td>
</tr>
<tr>
<td>Integration into value-based contracting</td>
<td>Data should be shared between manufacturers and clinicians to understand the impact of treatment in real-world settings</td>
</tr>
</tbody>
</table>

### Future State

**Development**
- Patients incorporated at initial stages and throughout drug development
- PROs widely integrated into clinical trial designs
- Utilize PROs that have both a predictive and historical perspective

**Validation**
- Utilize common terminology
- Identify PROs that are simple and validated yet customizable
- Identify PROs that are clinically sensitive and medically relevant
Future State

Adoption & Use
• PRO collection that is streamlined and efficient throughout a patient’s health or disease state
• Widespread integration of PRO endpoints into manufacturer labels

Analysis
• Identify a single platform for PRO collection and analysis
• Align clinician and payer incentives with PRO measurement and analysis
• Ensure PROs inform treatment decisions

Overarching Priorities to Achieve Future State

Common Framework or Terminology
Drive education
Inform best practices around care delivery and coverage determination

Meaningful Measures
Measures that have a ROI
Provide real-time insights to inform patient care or improve health

Technology and Infrastructure
EHR Integration
Better interoperability
Conclusions

PROs are important in fostering patient-centric care in drug development and creating care pathways

Barriers are limiting the greater use of PROs

Healthcare stakeholders must collaborate in developing best practices in drug development, clinical decision making and coverage decisions

Success contingent upon PROs that represent meaningful patient-driven measures

Reminder: How to Ask Questions During the Webinar
Next Steps – 2018 Forums

- **Designing Benefits and Payment Models for Innovative High-Investment Medications**, July 24-25, D.C.
- **Managing Total Cost of Care Through Medical and Pharmacy Integration**, Sept 25-26, D.C.
- **Building the Foundation for Patient Reported Outcomes: Infrastructure and Methodologies**, October 25, Orlando
- **Integrated Delivery Network’s Role in Value-Based Agreements for Pharmacy and Medical Benefits**, Nov 13-14, D.C.